Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Apr 8, 2025
Product Development

VEGF multispecifics get innovative at AACR 2025

New binding domains, target combinations and molecule structures define the VEGF multispecifics to be presented at AACR 2025
BioCentury | Apr 8, 2025
Data Byte

The expanding pipeline of VEGF multispecifics

At least 35 VEGF multispecific programs are in development
BioCentury | Apr 4, 2025
Management Tracks

Ex-Dyne team members reconvene at Crescent

Plus: New staff at Neurocrine, Xaira and Dark Blue; Oz confirmed at CMS
BioCentury | Apr 1, 2025
Distillery Therapeutics

Inhibiting T cell PCIF1 for antitumor immunity

BioCentury | Mar 29, 2025
Product Development

Bispecifics for I&I: Bypassing combination complexity

At least 30 companies have bispecific antibodies in development for autoimmune and inflammatory diseases
BioCentury | Mar 19, 2025
Product Development

Tempus aims for precision in complexity

With clinical records, patient samples and images in the millions, the diagnostics and data company is betting precision medicine can go multimodal
BioCentury | Feb 26, 2025
Distillery Therapeutics

Inhibition of cancer cell NDUFS4 for antitumor immunity

BioCentury | Feb 26, 2025
Distillery Therapeutics

Inhibiting P4HA1 for antitumor immunity

BioCentury | Feb 20, 2025
Product Development

Solid produces best-in-class biomarker data among DMD gene therapies

BioCentury’s latest Clinical Report highlights a pair of value-driving readouts
BioCentury | Feb 18, 2025
Product Development

Remaking Roche

How the once-dominant cancer company has overhauled its strategy for long-term growth
Items per page:
1 - 10 of 1310